BAH Booz Allen Hamilton Holding Corp Insider Trading

BAH CEO Rozanski buys 23,800 shares at $84.66, totaling $2.0M, amid -55.5% drop from 52-week high.

Rozanski purchased 23,800 shares at $84.66 on 2025-10-30, increasing his holdings by 3.6% to 687,745 shares. The purchase occurred as BAH's stock trades at $82.82, down 55.5% from its 52-week high of $186.00 and down 17.1% in the past 30 days. His prior five trades at BAH were all sales, with only 1 of 5 well-timed at the 90-day mark. This buy represents a shift in transaction direction after a series of dispositions, which occurs at a significant price inflection point: the stock is near its 52-week low. The timing context is material—the insider is purchasing during acute weakness rather than at elevated valuations—but the fundamental picture (12.4% annual revenue growth, P/E of 12.16, $2.9B quarterly revenue, $175.0M net income) provides supporting context for the decision.

Director Amble Joan Lordi bought 930 BAH shares at $130.90 on 2025-02-05, adding to 56.9K holdings. Stock down -31.2% from 52-week high.

Director Lordi purchased 930 shares at $130.90, representing a modest 1.7% increase to her 56.9K-share position at Booz Allen Hamilton. The timing of this purchase follows a sharp 90-day decline of -30.3% from recent highs, though the stock has stabilized over the past 30 days (-1.6%). Notably, Lordi's prior two open-market purchases at BAH (on 2024-11-22 and 2024-12-06) both experienced negative 30-day returns of -10.8% and -9.4% respectively, suggesting a pattern of purchases made during or shortly after selloffs that have not immediately recovered. The transaction occurs against a company backdrop of solid fundamentals: $2.9B in quarterly revenue, $187.0M net income, and +15.2% annual revenue growth, yet these positives have not arrested the recent stock price decline. This narrow purchase window—roughly 10 weeks after her December buy—warrants observation as to whether it reflects a redeployed conviction signal or a mechanical addition to existing holdings during a period of extended underperformance relative to her prior entry points.

Director Amble Joan Lordi bought 690 BAH shares at $145.66 on 2024-12-06 (total $100.5K); stock now -23.8% from 52-week high.

Director Amble Joan Lordi purchased 690 shares at $145.66, adding to holdings of 55,930 shares post-transaction. The timing coincides with significant price weakness: BAH is currently trading at $141.78, down 22.7% over 30 days and 23.8% from its 52-week high of $186.00. The company's fundamentals remain solid with annual revenue growth of 15.2%, net income of $390,112,000.00, and a P/E of 21.85 on a market cap of $18,115,619,644.32. This represents the director's second open-market purchase at BAH in two weeks, following a prior buy on 2024-11-22, suggesting continued accumulation during a period of market retreat.

Director Amble Joan Lordi bought 2,000 shares of BAH at $147.13; stock down 20.7% from 52-week high and -19.0% over 30 days.

Director Amble Joan Lordi purchased 2,000 shares at $147.13, increasing her holdings from 53,240 to 55,240 shares. The purchase occurred while Booz Allen Hamilton's stock has declined significantly: down 20.7% from its 52-week high of $186.00 and down 19.0% over the past 30 days, though the company maintains strong fundamentals with $3.1B in quarterly revenue, $390.1M in net income, and 15.2% annual revenue growth. The stock is currently trading at $147.46, slightly above the director's purchase price of $147.13. This buy by a sitting director in the context of substantial recent price weakness against stable underlying business performance warrants attention to whether market weakness is creating a buying opportunity or reflects deteriorating near-term prospects.

Laben Nancy (EVP & Chief Legal Officer) sold 11,984 shares of BAH at $180.96 on 2024-10-25 for $2,168,624.64, reducing holdings by 32.6%.

Laben sold 11,984 shares at $180.96, representing a 32.6% reduction in her BAH holdings from 36,789 to 24,805 shares. Her prior four BAH sales all posted negative 90-day returns, with a 100% on-sale timing pattern, but this sale occurred at precisely the 52-week high of $186.00, yet the stock has since remained flat at that peak. The transaction's magnitude—reducing holdings by roughly one-third—is material for a Chief Legal Officer, though the flat price action post-sale precludes confirmation of timing quality at this early stage.

CFO Calderone sells 4,065 BAH shares at $165.00 ($670.7K); retains 29.6K shares; stock now at $186.00 (+12.7% since sale).

Calderone, EVP & Chief Financial Officer, sold 4,065 shares on 2024-10-24 at $165.00, reducing his holding by 12.1% to 29,618 shares. The stock has subsequently appreciated to $186.00 (12.7% above the sale price) and is currently at its 52-week high. The CFO's same-ticker history shows a prior sale on 2024-09-23 that yielded 30d return of +2.0%, indicating prior sells at BAH have not been well-timed as a pattern. BAH's fundamentals remain robust, with annual revenue growth of 15.2%, quarterly revenue of $3.1B, net income of $390.1M, and a market cap of $23.8B, though the P/E of 28.66 reflects current valuation strength.

Crowe sells 4,243 BAH shares at $165.00 ($700.1K); holds 25,496 post-sale as stock rallies to $186.00.

Executive Vice President Richard Crowe sold 4,243 shares of Booz Allen Hamilton at $165.00 on 2024-10-24, reducing his stake from 29,739 to 25,496 shares (-14.3%). The sale occurred 22 days after BAH reached its 52-week high of $186.00, and the stock has since recovered to that peak price (+0.0% from 52-week high at transaction context). Booz Allen's fundamentals show strong momentum: annual revenue growth of +15.2%, quarterly net income of $390.1M, and a market cap of $23.8B, with the stock up +34.0% over 90 days. The trade represents a routine portfolio adjustment by a senior executive during a period of sustained stock appreciation.

CFO Calderone sold 3,865 shares of BAH at $160.00 on 2024-09-23, reducing stake 10.3% to 33.7K shares.

Matthew Calderone, EVP & Chief Financial Officer, sold 3,865 shares at $160.00, executed near the 52-week high of $160.29 and representing a 10.3% reduction in his pre-transaction holdings. The transaction occurred amid strong company fundamentals: $2.9B quarterly revenue with 15.2% annual growth, $165.2M net income, and a market cap of $20.7B. The stock trades at a P/E of 33.88 with recent momentum (30-day +3.9%, 90-day +2.3%), placing the sale at an elevated valuation on the stock's technical scale. Post-transaction, the CFO retains 33.7K shares, maintaining meaningful exposure to company performance.